Overall trial status: Ongoing, recruiting
Trial title: OptIMMize-2: A Phase 3 Multicenter, Single-arm, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of Risankizumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Completed Participation in Study M19-977 (OptIMMize-1).
Medical conditions: Plaque Psoriasis
Status in each country: Germany:Ongoing, recruiting, Spain:Ongoing, recruiting, Poland:Ongoing, recruiting
Trial phase: Therapeutic confirmatory (Phase III)
Therapeutic Areas: Diseases [C] - Immune System Diseases [C20]
Primary end point: Number of Participants With Adverse Events
Secondary end point: N/A
Age of participants: 0-17 years
Gender of participants: Female, Male
Trial region: In both EEA and non-EEA
Planned number of participants: 70
Sponsor: Abbvie Deutschland GmbH & Co. KG
Sponsor type: Pharmaceutical company
Trial product: Risankizumab, ABBV-066
Results posted: No
Overall decision date: 19/07/2022
Countries decision date: DE: 19/07/2022, ES: 19/07/2022, PL: 19/07/2022
Last updated date: 06/08/2026
Es gibt noch keine Rezensionen.